CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2014—MdxHealth’s ConfirmMDx for Prostate Cancer test was used as part of a multidisciplinary approach to confirm prostate cancer diagnosis using a technique called transperineal mapping biopsy. The cancer lesions found using this method were not detected by five conventional biopsies. The epigenetic test, performed on the residual prostate biopsy tissues, was able to confirm all the same areas of cancer lesions and locate additional regions of concern, the latter of which were confirmed after histopathological re-examination.
The case study was published online in the March 2014 Journal of OncoPathology (La Rosa FG, et al. Finding occult prostatic cancer: the value of transperineal mapping biopsies and epigenetic assays) by researchers from the University of Colorado and Maastricht University Medical Center, the Netherlands.
MdxHealth, 949-812-6979